The test, designed for noninvasive prenatal screening for trisomies 21, 18, and 13, with Y chromosome testing as an optional marker, has been validated in an external clinical study in France.
Recent Media Coverage
Read recent articles about PerkinElmer below. Clicking a headline will take you to the publication’s website for the full article.
David Wang, general manager of Informatics, explains how scientists can harness valuable information quickly to achieve better, faster outcomes—and expedite the drug discovery process—by taking "the 3Vs" into account.
AI comes in many forms, but machine learning and natural language processing are two which are helping drug discovery scientists find new drug candidates.
EUROIMMUN's Dr. Konstanze Stiba discusses the challenges associated with developing a diagnostic for "Disease X," which represents newly emerging pathogens that present a significant public health risk - with the potential for an international epidemic.
Sanofi Genzyme and PerkinElmer Genomics have launched a free genetic testing program that aims to spot certain undiagnosed lysosomal storage disorders, while raising awareness of the group of rare diseases whose symptoms may initially be ascribed to more common ailments.
Jamey Mock talks about the first 120 days in his role as PerkinElmer CFO.
PerkinElmer scientists are testing cannabis for pesticide and mycotoxin levels using an LC-MS/MS method.
Dennis Flannelly, Vice President of PerkinElmer Diagnostics, discusses the company’s exciting new offerings at AACC 2018, including the Vanadis NIPT Solution for non-invasive pre-natal testing.
Jim Cramer of CNBC 'Mad Money' sat down with Rob Friel, chairman and CEO of PerkinElmer. Shares of PerkinElmer (NYSE: PKI) are up 20% in 2018.
On this edition of Bloomberg Baystate Business, Rob Friel, CEO of PerkinElmer, talks about the company’s recently released second quarter earnings report.
The FDA has cleared PerkinElmer’s lupus diagnostics for sale in the U.S. PerkinElmer designed the tests to run on its automated EUROPattern microscope, thereby cutting turnaround times.
Although cisplatin is clinically proven to combat numerous human cancers – bladder, head and neck, lung, ovarian, testicular – resistance to treatment remains a key challenge, and cisplatin patients can often relapse.
Foundation Medicine and Illumina have amended their supply and service agreement and extended the terms of the agreement through June 6, 2023, according to a document filed with the US Securities and Exchange Commission by Foundation Medicine on Thursday.
This study uses single-cell inductively coupled plasma–mass spectrometry (ICP-MS) and discusses the steps required for a successful single-cell ICP-MS analysis using a mammalian case study of the uptake of cisplatin into ovarian cancer cells and an ecotoxicological example of the uptake of dissolved and nanoparticulate gold into freshwater algae cells.
Mass spectrometry is a go-to method for determining which molecules are in a sample. If security officers are faced with an unknown, possibly dangerous, substance, they don’t want to waste time sending samples to a lab and waiting for mass spec results, however. They’d rather be able to take a portable mass spec into the field to get answers quickly.
Elsevier has announced a strategic collaboration with PerkinElmer to integrate the companies chemistry software platforms.
Texas A&M AgriLife Research and their internationally recognized Genomics and Bioinformatics Service are poised to change the face of agriculture-focused genomics.
With the 2016 publication of ICH E6R2, organizations in the pharmaceutical space have been taking a fresh look at their Insource/Outsource strategies, in particular around analytics for clinical development.
Almost every industry is being exposed to the prevalence of opportunities provided by the internet of things (IoT). In fact, the number of connected “things” will reach 20.4 billion by 2020.